Kaken Pharmaceutical said on March 28 that its Spain-based licensing partner Almirall has earned regulatory approval in Italy for Jublia (efinaconazole), a topical treatment for onychomycosis. Jublia was discovered by Kaken and is marketed under the brand name of Clenafin…
To read the full story
Related Article
- Kaken’s Onychomycosis Drug Grabs German Approval
September 8, 2025
BUSINESS
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
- Retevmo Now Available in Tablet Form: Lilly Japan
December 8, 2025
- Japan Ethical Drug Sales Rise 5.9% in October: Crecon
December 8, 2025
- Takeda Closes Innovent Oncology Deal, Bags Rights to 2 Late-Stage Assets
December 8, 2025
- Santen to Market Bayer’s Eylea Bio-AG; Launch Date Still Undisclosed
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





